Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now small index

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) clinical trials

1 of 1 indexed Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) trials are currently recruiting.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP): 1 US clinical trial tracked, 1 recruiting.

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. The most active sponsor is Northwestern University, running 1 of these trials.

Enrollment posture brief

Registry condition chronic-rhinosinusitis-phenotype-with-nasal-polyps-crswnp

OPEN 1 | RECR 100% | LATE 0 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Chronic Rhinosinusitis P (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)

Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

Named interventions

Most-linked intervention names on Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Dupilumab - Standard Dose Drug
1 trials

US sites by state

Facility locations filed on Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) trials. A trial with sites in several states counts in each.

Illinois 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Northwestern University sponsors the most Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) trials on record, review their full trial history before evaluating a specific study. See Northwestern University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP) condition card totals 1 registered trials; most-linked intervention Dupilumab - Standard Dose; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.